Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Mairinger, F; Vollbrecht, C; Halbwedl, I; Hatz, M; Stacher, E; Gülly, C; Quehenberger, F; Stephan-Falkenau, S; Kollmeier, J; Roth, A; Mairinger, T; Popper, H.
Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma.
J Thorac Oncol. 2013; 8(5):644-653
Doi: 10.1097/JTO.0b013e318287c224
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Gülly Christian
- Halbwedl Iris
- Hofstadler Martina
- Popper Helmuth
- Quehenberger Franz
- Stacher-Priehse Elvira
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background: Malignant mesothelioma is a highly aggressive tumor arising from mesotheliallined surfaces, most often in the pleura cavities. Antifolates belong to the most effective cytotoxic drugs for malignant pleural mesothelioma (MPM) treatment. Pemetrexed is an antifolate inhibiting different folate pathway genes (thymidylate synthase [TS], dihydrofolate reductase, glycinamide ribonucleotide formyltransferase [GARFT], and aminoimidazole carboxamide ribonucleotide formyltransferase, [AICARFT]). Increased activity of pemetrexed occurs by folylpolyglutamate synthetase (FPGS), intracellular transport by reduced folate carrier (RFC). The aim of the study was to explore potential correlations between TS, GARFT, AICARFT, RFC, and FPGS levels in MPM and associations with clinical benefit from pemetrexed treatment. Methods: Samples from 63 patients were tested using immunohistochemistry (IHC) and quantitative polymerase chain reaction(qPCR) for expression levels of TS, GARFT, AICARFT, RFC, and FPGS. Clinical data were evaluated to determine associations between efficacy of pemetrexed and enzyme expression levels. Evaluation of expression levels was done through TaqManbased qPCR, and IHC was evaluated semiquantitatively by using the Hscore. Results: qPCR analysis showed no difference in expression pattern of GARFT and AICARFT. IHC analysis revealed a heterogeneous staining pattern for all the enzymes. No significant association was found between TS expression and survival or objective response of the tumors after pemetrexed treatment. FPGS (p = 0.0111) and RFC (p = 0.0088) mRNA expression levels were strongly associated with overall survival in these patients. Conclusions: Our results reveal that in pemetrexedtreated MPMs TS expression levels have no influence on patient outcome. Furthermore, GARFT and AICARFT were homogenously expressed in the patient samples. Folate uptake mechanisms by RFC and activation by FPGS were associated with clinical benefit from pemetrexed treatment.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Antimetabolites, Antineoplastic - therapeutic use
- Female -
- Gene Expression -
- Glutamates - therapeutic use
- Guanine - analogs & derivatives
- Humans -
- Kaplan-Meier Estimate -
- Male -
- Mesothelioma - enzymology
- Middle Aged -
- Peptide Synthases - genetics
- Phosphoribosylaminoimidazolecarboxamide Formyltransferase - genetics
- Phosphoribosylglycinamide Formyltransferase - genetics
- Pleural Neoplasms - enzymology
- Proportional Hazards Models -
- RNA, Messenger - metabolism
- Reduced Folate Carrier Protein - genetics
- Thymidylate Synthase - genetics
- Find related publications in this database (Keywords)
- Malignant pleural mesothelioma
- Pemetrexed
- Thymidylate Synthase
- Immunohistochemistry
- qPCR